{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:20:32Z","timestamp":1759422032560,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10072-023-06993-5","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T16:01:42Z","timestamp":1691078502000},"page":"4573-4574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eculizumab as a promising rescue therapy for acute exacerbations of myasthenia gravis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-386X","authenticated-orcid":false,"given":"Sohyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-5355","authenticated-orcid":false,"given":"Hung Youl","family":"Seok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"6993_CR1","doi-asserted-by":"publisher","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A, Iovino A, Piscosquito G, Calicchio G, Barone P (2023) Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-023-06900-y","DOI":"10.1007\/s10072-023-06900-y"},{"issue":"2","key":"6993_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"issue":"4","key":"6993_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91(4):392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"6993_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"3","key":"6993_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"6993_CR6","doi-asserted-by":"publisher","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF Jr (2020) Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol 11:556104. https:\/\/doi.org\/10.3389\/fneur.2020.556104","journal-title":"Front Neurol"},{"key":"6993_CR7","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M, Shimizu Y, Yokoyama K, Uzawa A, Kawaguchi N, Ikeguchi R, Hoshino Y, Hatano T et al (2020) Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13:1756286420904207. https:\/\/doi.org\/10.1177\/1756286420904207","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"6993_CR8","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","volume":"269","author":"CMM Strano","year":"2022","unstructured":"Strano CMM, Sorrenti B, Bosco L, Falzone YM, Fazio R, Filippi M (2022) Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. J Neurol 269(11):6152\u20136154. https:\/\/doi.org\/10.1007\/s00415-022-11222-8","journal-title":"J Neurol"},{"issue":"2","key":"6993_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 64(2):212\u2013215. https:\/\/doi.org\/10.1002\/mus.27326","journal-title":"Muscle Nerve"},{"issue":"1","key":"6993_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mus.26711","volume":"61","author":"C Farmakidis","year":"2020","unstructured":"Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ (2020) Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents. Muscle Nerve 61(1):17\u201325. https:\/\/doi.org\/10.1002\/mus.26711","journal-title":"Muscle Nerve"},{"issue":"7","key":"6993_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"2","key":"6993_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","volume":"30","author":"MR Tannemaat","year":"2020","unstructured":"Tannemaat MR, Verschuuren J (2020) Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord 30(2):111\u2013119. https:\/\/doi.org\/10.1016\/j.nmd.2019.12.003","journal-title":"Neuromuscul Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06993-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T02:06:55Z","timestamp":1699841215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6993"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06993-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}